Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.

ABSTRACT:

Purpose

To determine safety and feasibility of adjuvant ipilimumab following resection of high-risk melanoma and to identify surrogate markers for benefit.

Experimental design

In this phase II trial, 75 patients with resected stage IIIc/IV melanoma received the CTLA-4 antibody ipilimumab every 6 to 8 weeks for 1 year. Eligible patients received further maintenance treatments. The first 25 patients received 3 mg/kg of ipilimumab, and an additional 50 patients received 10 mg/kg. HLA-A*0201+ patients received multipeptide immunizations in combination with ipilimumab. Leukapheresis was performed prior to and 6 months after initiation of treatment.

Results

Median overall and relapse-free survivals were not reached after a median follow-up of 29.5 months. Significant immune

SUBMITTER: Sarnaik AA 

PROVIDER: S-EPMC3041838 | biostudies-literature | 2011 Feb

REPOSITORIES: biostudies-literature